BeiGene Limited (BGNE) is a biopharmaceutical company with a focus on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer. In this series, we’ll explore BeiGene’s financials, valuation, and analyst views.
BeiGene has three marketed in-licensed products: Abraxane, Revlimid, and Vidaza in China from Celgene. In September, it acquired Baiji Shenzhou Pharmaceuticals for a consideration of $612.0 million. The latter, a pharmaceutical distribution company, subsequently changed its name to BeiGene Pharmaceuticals.
Promising product pipeline
BeiGene also has three drug candidates in late stages of development: BGB-3111, BGB-A317, and BGB-290. BGB-3111 is a small molecule inhibitor of Bruton’s tyrosine kinase, BGB-A317 is a humanized monoclonal antibody for immune checkpoint inhibitor PD-1, and BGB-290 is a small molecule inhibitor of PARP1 and PARP2. The company has also filed two new drug applications for BGB-3111 in China and one new drug application for BGB-A317 in China.
Further, BeiGene also has three drug candidates in early development stages: BGB-283, BGB-A333, and BGB-A425. BGB-283 is an RAF dimer protein complex inhibitor, BGB-A333 is a humanized monoclonal antibody for immune checkpoint receptor ligand PD-L1, and BGB-A425 is a humanized monoclonal antibody for T-cell immunoglobulin and mucin domain containing-3. In November, BeiGene announced the dosing of the first patient in a global Phase 3 clinical trial of BGB-3111 compared to ibrutinib in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Next, we’ll look at BeiGene’s gross margin trends.